Transcutaneous immunization by merely prolonging the duration of antigen presence on the skin of mice induces a potent antigen-specific antibody response even in the absence of an adjuvant

Vaccine

Volumn 25, Issue 52, 2007, Pages 8762-8770

  Naito, Seishiro ^a   Maeyama, Jun ichi ^a   Mizukami, Takuo ^a   Takahashi, Motohide ^a   Hamaguchi, Isao ^a   Yamaguchi, Kazunari ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Adjuvant; Tetanus toxoid; Transcutaneous immunization

Indexed keywords

CHOLERA TOXIN; TETANUS TOXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIBODIES, BACTERIAL; FEMALE; IMMUNIZATION; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; OVALBUMIN; SURVIVAL ANALYSIS; TETANUS; TETANUS TOXOID; TIME FACTORS;

EID: 36549044395     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.10.031     Document Type: Article

References (41)

1. Bos J.D. The skin as an organ of immunity. Clin Exp Immunol 107 Suppl. 1 (1997) 3-5
2. Chuong C.M., Nickoloff B.J., Elias P.M., Goldsmith L.A., Macher E., Maderson P.A., et al. What is the 'true' function of skin?. Exp Dermatol 11 (2002) 159-187
3. Glenn G.M., Rao M., Matyas G.R., and Alving C.R. Skin immunization made possible by cholera toxin. Nature 391 (1998) 851
4. Beignon A.S., Briand J.P., Muller S., and Partidos C.D. Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge. Immunol 102 (2001) 344-351
5. Godefroy S., Goestch L., Plotnicky-Gilquin H., Nguyen T.N., Schmitt D., Staquet M.J., et al. Immunization onto shaved skin with a bacterial enterotoxin adjuvant protects mice against Respiratory Syncytial Virus (RSV). Vaccine 21 (2003) 1665-1671
6. Berry L.J., Hickey D.K., Skelding K.A., Bao S., Rendina A.M., Hansbro P.M., et al. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun 72 2 (2004) 1019-1028
7. Skountzou I., Quan F.S., Jacob J., Compans R.W., and Kang S.M. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine 24 (2006) 6110-6119
8. Hammond S.A., Guebre-Xabier M., Yu J., and Glenn G.M. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy. Crit Rev Ther Drug Carrier Syst 18 5 (2001) 503-526
9. Partidos C.D., Beignon A.S., Briand J.P., and Muller S. Modulation of immune responses with transcutaneously deliverable adjuvants. Vaccine 22 (2004) 2385-2390
10. Glenn G.M., Scharton-Kersten T., Vassell R., Matyas G.R., and Alving C.R. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun 67 3 (1999) 1100-1106
11. Warger T., Schild H., and Rechtsteiner G. Initiation of adaptive immune responses by transcutaneous immunization. Immunol Lett 109 (2007) 13-20
12. Glenn G.M., Taylor D.N., Li X., Frankel S., Montemarano A., and Alving C.R. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nature Med 6 12 (2000) 1403-1406
13. Rechtsteiner G., Warger T., Osterloh P., Schild H., and Radsak M.P. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 174 5 (2005) 2476-2480
14. Tierney R., Beignon A.S., Rappuoli R., Muller S., Sesardic D., and Partidos C.D. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody. J Infect Dis 188 5 (2003) 753-758
15. John M., Bridges E.A., Miller A.O., Calderwood S.B., and Ryan E.T. Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies. Vaccine 20 21-22 (2002) 2720-2726
16. Scharton-Kersten T., Yu J., Vassell R., O'Hagan D., Alving C.R., and Glenn G.M. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun 68 9 (2000) 5306-5313
17. Zhao Y.L., Murthy S.N., Manjili M.H., Guan L.J., Sen A., and Hui S.W. Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization. Vaccine 24 9 (2006) 1282-1290
18. Tezel A., Paliwal S., Shen Z., and Mitragori S. Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine 23 (2005) 3800-3807
19. Mckenzie R., Bourgeois A.L., Frech S.A., Flyer D.C., Bloom A., Kazempour K., et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 25 18 (2007) 3684-3691
20. Mishra V., Mahor S., Rawat A., Dubey P., Gupta P.N., Singh P., et al. Development of novel fusogenic vesosomes for transcutaneous immunization. Vaccine 24 27-28 (2006) 5559-5570
21. Heckert R.A., Elankumaran S., Oshop G.L., and Vakharia V.N. A novel transcutaneous plasmid-dimethylsulfoxide delivery technique for avian nucleic acid immunization. Vet Immunol Immunopathol 89 1-2 (2002) 67-81
22. Chen D., Colditz I.G., Glenn G.M., and Tsonis C.G. Effect of transcutaneous immunization with co-administered antigen and cholera toxin on systemic and mucosal antibody responses in sheep. Vet Immunol Immunopathol 86 3-4 (2002) 177-182
23. Yu J., Cassels F., Scharton-Kersten T., Hammond S.A., Hartman A., Angov E., et al. Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect Immun 70 3 (2002) 1056-1068
24. Morrow C.K., Colditz I.G., and Cope R.B. Stimulated solar UVB exposure inhibits transcutaneous immunization to cholera toxin via an irradiated skin site in cattle. Vet immunol immunopathol 83 1-2 (2001) 107-114
25. Godefroy S., Peyre M., Garcia N., Muller S., Seardic D., and Partidos C.D. Effect of skin barrier disruption on immune responses to topically applied cross-reacting material, CRM(197), of diphtheria toxin. Infect Immun 73 8 (2005) 4803-4809
26. Frankenburg S., Grinberg I., Bazak Z., Fingerut L., Pitcovski J., Gorodetsky R., et al. Immunological activation following transcutaneous delivery of HR-gp100 protein. Vaccine 25 23 (2007) 4564-4570
27. Paul A., Ceve G., and Bachhawat B.K. Transdermal immunization with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. Vaccine 16 2-3 (1998) 188-195
28. Ghose C., Kalsy A., Sheikh A., Rollenhagen J., John M., Young J., et al. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect Immun 75 6 (2007) 2826-2832
29. Matyas G.R., Friedlander A.M., Glenn G.M., Little S., Yu J., and Alving C.R. Needle-free skin patch vaccination method for anthrax. Infect Immun 72 2 (2004) 1181-1183
30. Baca-Estrada M.E., Ewen C., Mahony D., Babiuk L.A., Wilkie D., and Foldvari M. The haemopoietic growth factor, Flt3L, alters the immune response induced by transcutaneous immunization. Immunology 107 1 (2002) 69-76
31. Ya-Xian Z., Suetake T., and Tagami H. Number of cell layers of the stratum corneum in normal skin-relationship to the anatomical location on the body, age, sex and physical parameters. Arch Dermatol Res 291 (1999) 555-559
32. Bronaugh R.L., and Maibach H.I. Topical absorption of dermatological products (2002), Marcel Dekker, Inc., New York
33. Hickey D.K., Bao S., Ikeda L.T., Carey A.J., and Beagley K.W. Induction of anti-chlamydial mucosal immunity by transcutaneous immunization is enhanced by topical application of GM-CSF. Curr Mol Med 5 6 (2005) 599-605
34. Partidos C.D., Moreau E., Chaloin O., Tunis M., Briand J.P., Desgranges C., et al. A synthetic HIV-1 Tat protein breaches the skin barriers and elicits Tat-neutralizing antibodies and cellular immunity. Eur J Immunol 34 12 (2004) 3723-3731
35. Seo N., Tokura Y., Nishijima T., Hashizume H., Furukawa F., and Takigawa M. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc Natl Acad Sci USA 97 1 (2000) 371-376
36. Nikolic W.V., Bai Y., Obregon D., Hou H., Mori T., Zeng J., et al. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc Natl Acad Sci USA 104 7 (2007) 2507-2512
37. Nishijima T., Tokura Y., Imokawa G., Seo N., Furukawa F., and Takigawa M. Altered permeability and disordered cutaneous immunoregulatory function in mice with acute barrier disruption. J Invest Dermatol 109 2 (1997) 175-182
38. Scharton-Kersten T., Glenn G.M., Vassell R., Yu J., Walwender D., and Alving C.R. Principles of transcutaneous immunization using cholera toxin as an adjuvant. Vaccine 17 (1999) S37-S43
39. Elson C.O., and Ealding W. Genetic control of the murine immune response to cholera toxin. J Immunol 135 (1985) 930-932
40. Elson C.O., and Ealding W. Ir gene control of the murine secretory IgA response to cholera toxin. Eur J Immunol 17 (1987) 425-428
41. Elson C.O. Cholera toxin as a mucosal adjuvant: effects of H-2 major histocompatibility complex and lps genes. Infect Immun 60 (1992) 2874-2879